Brief: Scynexis Initiates Phase 1 Study Of Scy-770, A Novel Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (Adpkd)
30/06/2026 13:37
BRIEF-Scynexis Initiates Phase 1 Study Of Scy-770, A Novel Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (Adpkd) June 30 (Reuters) - SCYNEXIS Inc SCYX.O:
SCYNEXIS INITIATES PHASE 1 STUDY OF SCY-770, A NOVEL AMPK ACTIVATOR FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
SCYNEXIS - PHASE 2 STUDY IN ADPKD EXPECTED TO BEGIN IN Q4 2026
SCYNEXIS - TOPLINE PHASE 1 DATA EXPECTED IN Q3 2026
Source text: ID:nGNX7N5Sv5
Further company coverage: SCYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview